Compare CHEF & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHEF | IOVA |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2011 | 2008 |
| Metric | CHEF | IOVA |
|---|---|---|
| Price | $64.33 | $3.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $76.83 | $9.11 |
| AVG Volume (30 Days) | 424.4K | ★ 16.9M |
| Earning Date | 05-12-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | 14.84 |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $1,301,520,000.00 | N/A |
| Revenue This Year | $8.88 | $49.14 |
| Revenue Next Year | $7.64 | $51.69 |
| P/E Ratio | $38.08 | ★ N/A |
| Revenue Growth | ★ 9.11 | N/A |
| 52 Week Low | $45.00 | $1.64 |
| 52 Week High | $73.94 | $5.63 |
| Indicator | CHEF | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 52.57 |
| Support Level | $60.76 | $1.99 |
| Resistance Level | $65.47 | $4.34 |
| Average True Range (ATR) | 2.40 | 0.50 |
| MACD | -0.54 | -0.00 |
| Stochastic Oscillator | 35.43 | 28.72 |
The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.